Rebecca Araujo

DocwireNews

The Food and Drug Administration (FDA) announced that they will hold a public meeting of the Oncologic Drugs Advisory Committee to discuss six indications for oncology drugs that were granted accelerated approval. Following the approvals, results from confirmatory trials have not verified clinical benefit of these agents.The meeting will take place from April 27th to 29th, 2021.The six indications up for discussion are:<ul>
<li>Atezolizumab, approved in combination with paclitaxel protein-bound for the treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer whose tumors express PD-L1 expression; and for treatment of adults with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-containing chemotherapy.</li>
<li>Pembrolizumab, for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-containing chemotherapy; for treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1, with disease progression after &ge;2 prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu-targeted therapy; and for treatment of patients with hepatocellular carcinoma who were previously treated with sorafenib.</li>
<li>Nivolumab, for the treatment of patients with hepatocellular carcinoma who were previously treated with sorafenib.</li>
</ul>&ldquo;We are committed to ensuring the integrity of the accelerated approval program, which is designed to bring safe and effective drugs to patients with unmet medical needs as quickly as possible,&rdquo; said Richard Pazdur, MD, director of the FDA&rsquo;s Oncology Center of Excellence, via a <a href="https://www.fda.gov/news-events/fda-brief/fda-brief-fda-oncologic-drugs-advisory-committee-review-status-six-indications-granted-accelerated">press release</a>. &ldquo;When confirmatory trials do not confirm clinical benefit, a reevaluation must be performed to determine if the approval should be withdrawn.&rdquo;

Jordana Jampel

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Eric Bergson, MD

Rob Dillard

The Role of Multidisciplinary Care in Head and Neck Cancer

Head and Neck Cancer

Sara Nunnery, MD, MSCI

Trastuzumab Deruxtecan in HER2-Low Breast Cancer: Who’s the Right Patient?

HER2 Breast Cancer

Latest News

FDA Will Re-Evaluate Accelerated Approval for Six Cancer Drugs

Oncology

The Food and Drug Administration (FDA) announced that they will hold a public meeting of the Oncologic Drugs Advisory Committee to discuss six indications for oncology drugs ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe